Analysts/Institutional Investor Meet/Con. Call Updates4 Nov 2026 · 19:15
Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript
Markets / Nifty 50 / Healthcare
Price
Daily closing prices, adjusted for bonuses and splits
Returns against the Nifty 50
| Return | 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| SUNPHARMA | +0.9% | −0.4% | −8.6% | −4.2% | +4.9% | +55.4% | +122.9% |
| Nifty 50 | +5.6% | +6.2% | −2.7% | −1.5% | −6.4% | +24.6% | +33.7% |
Price returns, without dividends. Source: NSE end-of-day data.
Check-up
Where SUNPHARMA sits against the Nifty 50 and its industry. Facts, not advice.
Price return
+4.93%
Over 1 year. The Nifty 50 returned −6.40%, so SUNPHARMA beat it by 11.3 percentage points.
Valuation (PE)
38.8
Price is 38.8 times the last four quarters' earnings per share, higher than the Nifty 50's PE of 19.8 and the 4 industry peers' median of 48.1.
Growth
+11.9%
Revenue in Q2 FY27 compared with the same quarter a year earlier. Net profit changed −36.2%.
Profitability (ROE)
12.3%
Profit over the last four quarters as a share of shareholders' equity. Net margin is 17.8%.
Debt
0.03×
Borrowings are 0.03 times shareholders' equity (latest balance sheet, 30 Sep 2026).
Volatility
1.40×
Daily price moves over the last year were 1.40 times as large as the Nifty 50's (annualised volatility 19.3%).
What the latest numbers show
Calculated by stockER from the company's filings and NSE data.
Positives 4
- Revenue up 11.9% from a year ago₹16,199 cr in Q2 FY27, against ₹14,478 cr in Q2 FY26.
- Borrowings fell 42.5% in a year₹2,693 cr on 30 Sep 2026, against ₹4,686 cr a year earlier.
- Operating cash flow of ₹12,419 crCash generated by the business in the year to 31 Mar 2026.
- Mutual fund holding up 0.60 points in a year13.01% on 30 Sep 2026, from 12.41%.
Watch points 4
- Net profit down 36.2% from a year ago₹1,995 cr in Q2 FY27, against ₹3,125 cr in Q2 FY26.
- Net margin narrowed to 12.3%From 21.6% in Q2 FY26.
- Promoter holding down 1.80 points in a year52.68% on 30 Sep 2026, from 54.48%.
- Foreign institutional holding down 2.19 points in a year14.36% on 30 Sep 2026, from 16.55%.
Financials
Consolidated results as filed with NSE. ₹ crore unless stated.
Revenue
Net profit
EPS (₹)
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 | 16,199 |
| Other income | 466 | 613 | 464 | 470 | 579 | 458 | 724 | 517 |
| Total expenses | 10,349 | 9,956 | 10,325 | 10,781 | 11,383 | 11,519 | 11,721 | 12,288 |
| EBITDA | 4,158 | 3,967 | 3,948 | 4,997 | 5,038 | 4,413 | 4,937 | 3,992 |
| Depreciation | 631 | 664 | 701 | 730 | 732 | 775 | 739 | 758 |
| Finance cost | 52 | 49 | 75 | 100 | 78 | 86 | 100 | 75 |
| PBIT | 3,528 | 3,303 | 3,248 | 4,267 | 4,306 | 3,637 | 4,198 | 3,234 |
| Profit before tax | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 | 3,159 |
| Tax | 559 | 1,094 | 870 | 1,031 | 826 | 828 | 1,188 | 1,158 |
| Net profit | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 | 1,995 |
| EPS (₹) | 12.10 | 9.00 | 9.50 | 13.00 | 14.00 | 11.30 | 12.10 | 8.30 |
| ₹ crore | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue from operations | 43,886 | 48,497 | 52,578 | 58,462 |
| Other income | 635 | 1,354 | 1,965 | 1,972 |
| Total expenses | 34,940 | 38,269 | 40,114 | 44,007 |
| EBITDA | 12,110 | 13,883 | 16,559 | 18,396 |
| Depreciation | 2,529 | 2,557 | 2,575 | 2,938 |
| Finance cost | 172 | 238 | 231 | 339 |
| PBIT | 9,580 | 11,326 | 13,983 | 15,458 |
| Profit before tax | 9,408 | 11,088 | 13,752 | 15,119 |
| Tax | 848 | 1,439 | 2,772 | 3,554 |
| Net profit | 8,513 | 9,610 | 10,965 | 11,509 |
| ₹ crore | MAR 2024 | SEP 2024 | MAR 2025 | SEP 2025 | MAR 2026 | SEP 2026 |
|---|---|---|---|---|---|---|
| Total assets | 85,463 | 88,116 | 92,101 | 1,03,706 | 1,08,785 | 1,14,838 |
| Current assets | 43,433 | 46,069 | 52,594 | 60,136 | 63,860 | 69,267 |
| Inventories | 9,868 | 9,936 | 10,243 | 10,442 | 11,493 | 12,592 |
| Cash and equivalents | 9,286 | 8,013 | 10,269 | 10,022 | 9,771 | 18,401 |
| Total liabilities | 18,357 | 18,736 | 19,615 | 25,580 | 24,905 | 25,275 |
| Current liabilities | 16,984 | 17,255 | 18,194 | 23,415 | 22,622 | 23,592 |
| Borrowings | 2,846 | 2,081 | 1,870 | 4,686 | 4,082 | 2,693 |
| Shareholders' equity | 67,106 | 69,380 | 72,486 | 78,127 | 83,880 | 89,564 |
| Equity attributable to owners | 63,667 | 69,115 | 72,218 | 77,820 | 83,570 | 89,280 |
Balance sheets are filed every half year (September and March).
| ₹ crore | 6M to SEP 2022 | 12M to MAR 2025 | 6M to SEP 2025 | 12M to MAR 2026 | 6M to SEP 2026 |
|---|---|---|---|---|---|
| From operations | −939 | 14,072 | 4,781 | 12,419 | 3,141 |
| From investing | −1,356 | −5,306 | −6,691 | −11,344 | 8,307 |
| From financing | 1,956 | −7,906 | 1,101 | −2,513 | −2,937 |
| Capital expenditure | 1,076 | 2,129 | 2,388 | 3,609 | 1,785 |
| Free cash flow | −2,015 | 11,944 | 2,393 | 8,810 | 1,356 |
Cash flow statements are filed every half year; figures are for the period shown.
EBITDA here is profit before tax plus finance cost and depreciation. Annual figures add up the four quarters of each financial year. Source: company filings on NSE (XBRL).
Peers
Healthcare companies in the Nifty 50.
| Company | Price | Market cap | PE | PB | ROE | Div. yield | 1Y return |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹1,773.40 | ₹4.25 lakh cr | 38.8 | 4.77 | 12.3% | 0.90% | +4.9% |
| Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹8,599.50 | ₹1.24 lakh cr | 55.1 | 11.66 | 21.1% | 0.23% | +10.1% |
| Dr. Reddy's Laboratories Ltd.DRREDDY | ₹1,374.00 | ₹1.15 lakh cr | 41.0 | 2.96 | 7.2% | 0.58% | +14.5% |
| Cipla Ltd.CIPLA | ₹1,402.00 | ₹1.13 lakh cr | 39.1 | 3.20 | 8.2% | 0.93% | −6.7% |
| Max Healthcare Institute Ltd.MAXHEALTH | ₹927.15 | ₹90,240 cr | 65.4 | 7.96 | 12.2% | 0.22% | −18.6% |
Price comparison
Change in price from the start of the period
SUNPHARMANifty 50APOLLOHOSPDRREDDY
Events
Dividends, bonuses and splits from NSE's corporate actions.
Dividend paid in 5 of the last 5 calendar years (2022–2026)Over the last 12 months: ₹16.00 per share (adjusted for bonuses and splits), a yield of 0.90% at today's price.
Past dividends
Dividend
Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
7 Jul 2026
Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
7 Jul 2026
Interim dividend
Interim Dividend - Rs 11 Per SharePer share
₹11.00Ex-date
5 Feb 2026
Interim Dividend - Rs 11 Per SharePer share
₹11.00Ex-date
5 Feb 2026
Dividend
Dividend - Rs 5.50 Per SharePer share
₹5.50Ex-date
7 Jul 2025
Dividend - Rs 5.50 Per SharePer share
₹5.50Ex-date
7 Jul 2025
Interim dividend
Interim Dividend - Rs 10.50 Per SharePer share
₹10.50Ex-date
6 Feb 2025
Interim Dividend - Rs 10.50 Per SharePer share
₹10.50Ex-date
6 Feb 2025
Dividend
Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
12 Jul 2024
Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
12 Jul 2024
Interim dividend
Interim Dividend - Rs 8.50 Per SharePer share
₹8.50Ex-date
9 Feb 2024
Interim Dividend - Rs 8.50 Per SharePer share
₹8.50Ex-date
9 Feb 2024
Dividend
Dividend - Rs 4 Per SharePer share
₹4.00Ex-date
28 Jul 2023
Dividend - Rs 4 Per SharePer share
₹4.00Ex-date
28 Jul 2023
Interim dividend
Interim Dividend - Rs 7.50 Per SharePer share
₹7.50Ex-date
8 Feb 2023
Interim Dividend - Rs 7.50 Per SharePer share
₹7.50Ex-date
8 Feb 2023
Bonuses, splits and other actions
Buy BackEx-date
14 Jul 2016
14 Jul 2016
Filings and updates
The company's own announcements to NSE: results, dividends, presentations and board decisions.
Annual report 2025–26Open (PDF / ZIP)
Annual report 2024–25Open (PDF / ZIP)
Annual report 2023–24Open (PDF / ZIP)
Annual report 2022–23Open (PDF / ZIP)
Annual report 2021–22Open (PDF / ZIP)
General Updates31 Oct 2026 · 20:14
Completion and Results of Postal Ballot dated 01 October 2026
Analysts/Institutional Investor Meet/Con. Call Updates30 Oct 2026 · 20:13
Sun Pharmaceutical Industries Limited has informed the Exchange about Link of Recording
General Updates30 Oct 2026 · 15:18
Appointment of Statutory Auditors Pursuant to Mandatory Auditor Rotation
Outcome of Board Meeting30 Oct 2026 · 14:15
Unaudited Financial Results for the quarter and half year ended 30 September 2026
Press Release30 Oct 2026 · 08:05
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis".
Allotment of Securities26 Oct 2026 · 12:30
Sun Pharmaceutical Industries Limited has informed the Exchange regarding allotment of 781600 securities pursuant to Non Convertible Securities at its meeting held on October 26, 2026
Press Release23 Oct 2026 · 18:01
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 23, 2026.
Press Release20 Oct 2026 · 17:35
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.
Analysts/Institutional Investor Meet/Con. Call Updates15 Oct 2026 · 18:18
Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet
Credit Rating13 Oct 2026 · 17:54
Sun Pharmaceutical Industries Limited has informed the Exchange about Credit Rating
Resignation of Director/KMP/SMP12 Oct 2026 · 20:34
Sun Pharmaceutical Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP
Frequently asked questions
What is the share price of Sun Pharmaceutical Industries Ltd. (SUNPHARMA)?
SUNPHARMA closed at ₹1,773.40 on NSE on 4 Nov 2026, +0.20% on the day. stockER shows end-of-day prices, updated after the market closes.
What is the market cap of SUNPHARMA?
₹4.25 lakh cr, based on 239.93 crore shares and the latest closing price. That makes it #13 by size in the Nifty 50.
What are the PE and PB ratios of SUNPHARMA?
PE 38.80 on earnings per share of ₹45.70 over the last four quarters; PB 4.77 on the latest reported equity.
What is the 52-week high and low of SUNPHARMA?
High ₹2,046.90 on 31 Jul 2026, low ₹1,583.70 on 29 Jan 2026 (adjusted for bonuses and splits).
What is the dividend yield of SUNPHARMA?
0.90%: dividends of ₹16.00 per share with ex-dates in the last 12 months, divided by the latest price.
What return has SUNPHARMA given?
1 year +4.9%, 3 years +55.4%, 5 years +122.9% (price only, dividends not included).
Which sector is SUNPHARMA in?
NSE classifies Sun Pharmaceutical Industries Ltd. under Healthcare. Other Nifty 50 companies in it: APOLLOHOSP, CIPLA, DRREDDY, MAXHEALTH.
Who owns SUNPHARMA?
On 30 Sep 2026, promoters held 52.68% and the public 47.32%.
How can I buy SUNPHARMA shares?
Through a SEBI-registered stockbroker with a demat and trading account. stockER is an information site only: it doesn't sell shares or recommend buying or selling any of them.